Logo Image

News

Chemotherapy Development is ‘In’ Again

ByMoe Alsumidaie

Applied Clinical Trials

Cancer therapy development has advanced to researching targeted immunotherapies and moving into gene-specific therapies. Some companies, however, are focusing on reviving cytotoxic therapies that were too toxic for patients when administered generally. Bill Newell, Chief Executive Officer of Sutro Biopharma, sits down with Moe Alsumidaie to discuss the use of a cell-free protein synthesis approach.

Screen Shot 2019-04-22 at 9.48.50 AM.png

Understanding the Statistical Implications of Undetected Risk

ByMoe Alsumidaie

Applied Clinical Trials

Nonadherence in clinical trials plays a significant role in influencing the quality of data, trial results and, subsequently trial cost and duration. It may stem from unintentional drivers, such as forgetfulness, poor organizational skills, protocol regimen complexity, or experiencing an Adverse Event.